Wednesday, April 13, 2022
Cocrystal Pharma Inc. (COCP)
First Results From Influenza Program Announced
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
First Data From Influenza Program Reported. Cocrystal reported preliminary data from the Phase 1 clinical trial testing CC-42344, its oral antiviral for pandemic and seasonal influenza A. This is an orally administered drug that targets viral polymerase, blocking an early step in the viral lifecycle. The first two cohorts receiving single ascending doses of CC-42344 showed favorable safety and pharmacokinetic profiles.
The Phase 1 Trial Continues. The announcement was based on the first two cohorts treated with single doses of 100mg and 200mg and demonstrated safety with a favorable pharmacokinetic profile. To date, CC-42344 has shown strong bioavailablity, plasma levels that correlated with doses given, and a half-life that supports oral daily dosing. The trial has a target enrollment of 56 healthy adults and is …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
